iiinova — where your digital self keeps evolving

Reposted by Nico Gagelmann

Dana-Farber Cancer Institute @danafarber.bsky.social · 06/12/2025

@nicogagelmann.bsky.social shares findings that longer telomeres in donors ≥35 are associated with reduced graft failure and lower non-relapse mortality following allogeneic HCT. #ASH25

031

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 01/12/2025

Don't get left out at sea! Prepare now for ASH-a-Palooza at #ASH25🐬 ◽Sign up early for Blood Buddy speed mentoring: ow.ly/Cafw50XA6Gt ◽Arrive by 11:45 a.m. for the Global Hematology Trainee Networking Lunch ◽Join the AAP treasure hunt ( in the #ASH25 app) #ASHTrainee ASH Education

031

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 03/12/2025

The #ASH25 virtual platform is now live! Log in now using the ASH username and password you used to register for the annual meeting: ow.ly/MmlR50XBiMT 🌟Your bonus and preview content await. Plus, explore networking, exhibits, and more on the virtual platform! #HemeSky #MedSky

041

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 25/11/2025

Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily. Read now: ow.ly/tEgJ50XxAP6 #HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt

193

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 27/11/2025

The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏 #ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25 International community, share your throwbacks from past ASH meetings! #HemeSky

062

Nico Gagelmann @nicogagelmann.bsky.social · 12/10/2025

Finally in Boston! Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social. A place of science, purpose and hope.

130

Nico Gagelmann @nicogagelmann.bsky.social · 29/09/2025

Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️ Faculty who fight REAL debates Audience that ask REAL questions Unity amid controversy🙏 See you 1-3 October 2026 in Berlin again!

000

Nico Gagelmann @nicogagelmann.bsky.social · 28/07/2025

Last Call for Early Bird Registration Join us at the 10th COSTEM Congress! 🗓️ September 25–28, 2025 📍 Berlin, Germany Don't miss your chance to save – Early Bird registration closes July 31st! costem.cme-congresses.com/registration/

costem.cme-congresses.com

Registration - COSTEM Congress 2025

Registration for COSTEM 2025

000

Reposted by Nico Gagelmann

VJHemOnc @vjhemonc.bsky.social · 18/02/2025

🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe: 👉 buff.ly/4gBhWeD #ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky

051

Reposted by Nico Gagelmann

Nihar Desai MD, DM @nihardesai7.bsky.social · 12/02/2025

Out now in Blood Advances 🙌🏽 Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation! Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽 ashpublications.org/bloodadvance...

074

Nico Gagelmann @nicogagelmann.bsky.social · 08/02/2025

MAKE CAR-T AFFORDABLE AGAIN Terrific learning experience from cellular therapy programs in India, Slovenia, Brazil and Turkey #CART25

010

Nico Gagelmann @nicogagelmann.bsky.social · 27/01/2025

Let's learn hematology in 2025🩸 Day 27: hemophilia characteristics

010

Reposted by Nico Gagelmann

NEJM.org @nejm.org · 10/01/2025

In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn #MedSky

nej.md

Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...

0165

Reposted by Nico Gagelmann

NEJM.org @nejm.org · 09/01/2025

Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn

142

Reposted by Nico Gagelmann

Anand Patel @anand-88-patel.bsky.social · 09/01/2025

a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT! www.nejm.org/doi/full/10....

274

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 10/12/2024

#ASHKudos for the award. Glad that you had fun at #ASH24!

041

Nico Gagelmann @nicogagelmann.bsky.social · 10/12/2024

What a wonderful #ASH24 Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego. Until next year 🙏🩸❤️

180

Reposted by Nico Gagelmann

VJHemOnc @vjhemonc.bsky.social · 07/12/2024

Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱 Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀

111

Reposted by Nico Gagelmann

Anand Patel @anand-88-patel.bsky.social · 07/12/2024

Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF -1800 rux treated pts -early allo in high-risk PMF and SMF seems to be best timing -early allo in TP53 may offer survival benefit

152

Nico Gagelmann @nicogagelmann.bsky.social · 06/12/2024

🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉 Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm t.co/F7QjOoavKO

t.co

https://www.nature.com/articles/s41408-024-01197-2

061

Nico Gagelmann @nicogagelmann.bsky.social · 04/12/2024

Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24: -Cilta-cel with better ORR, CR, PFS -Similar NRM -Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel 👉associated with response and with ICANS for cilta-cel @ash-hematology.bsky.social

050

Reposted by Nico Gagelmann

Ajay Major, MD, MBA @majorajay.bsky.social · 02/12/2024

Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (buff.ly/3Zy7BLc) and BS (buff.ly/3B9SpKU), so please do follow! buff.ly/49iWb1d

191

Nico Gagelmann @nicogagelmann.bsky.social · 01/12/2024

#ASH24 of the day: Talquetamab Bridging before CAR-T -Talq bridging: 62% ORR (14% CR) -Post-CAR-T: 97.5% ORR (35% CR) -Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS) -Post-CAR-T: less CRS (65%), ICANS (2% grade 3) Should be standard of care #mmsm @ash-hematology.bsky.social

042

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 30/11/2024

🌟 Attention trainees! ASH-a-Palooza is just one week away! There’s still time to register for this trainee-focused party full of beats, free bites, & burst of learning. Kicking off #ASH24 next Friday! Register: bit.ly/ASH-a-Palooza #ASHTrainee #HemeSky #Hematology #Fellow #MedSky #HemeOnc

0176

Nico Gagelmann @nicogagelmann.bsky.social · 27/11/2024

This platform is also the place to share and circulate: Donate blood🙏🩸 Donate stem cells🙏🩸 It doesnt hurt and save lives. Be a hero, in the real world. Be a hero here, and spread the word. #donate #medsky #bmtsm

060

Nico Gagelmann @nicogagelmann.bsky.social · 27/11/2024

Science and medicine should NEVER EVER mix with politics🙏

020

Nico Gagelmann @nicogagelmann.bsky.social · 26/11/2024

20 people work for @bsky.app in Seattle. These 20 people ensure freedom of communication🤣🤣

010

Nico Gagelmann @nicogagelmann.bsky.social · 25/11/2024

The world needs resonance, not following not likes. Real engagement is what makes the world a better place and helps you find real friends.

040

Nico Gagelmann @nicogagelmann.bsky.social · 24/11/2024

Why did the platelet bring a date to the clot? Because it didn’t want to stick around alone!

010

Reposted by Nico Gagelmann

Dr Neil Stone @drneilstone.bsky.social · 24/11/2024

I have a meropenem joke but I won't let you use it

1202

Nico Gagelmann @nicogagelmann.bsky.social · 24/11/2024

Follow me on #Bluesky because the future deserves your good taste in people🤣

010

Nico Gagelmann @nicogagelmann.bsky.social · 24/11/2024

I was going to tell you a chemistry joke, but I didn’t think it would get a reaction.

060

Nico Gagelmann @nicogagelmann.bsky.social · 24/11/2024

ASH is amazing, cant wait for #ASH24🙏❤️🙏

010

Reposted by Nico Gagelmann

American Society of Hematology @ash.hematology.org · 21/11/2024

Hello, #hematology community! ASH is now on BlueSky. We're here to share cutting-edge research and educational resources and connect global experts in blood diseases. Join us in advancing hematology together. Welcome, colleagues! #BloodSky #HemeSky #MedSky

38817

Reposted by Nico Gagelmann

Bruce Levine, Ph.D. 🇺🇦 @bllphd.bsky.social · 21/11/2024

Bluesky is the new destination for X/Twitter’s health and science community. Here’s why #MedSky #ScienceSky 🥼🧪https://www.statnews.com/2024/11/21/bluesky-gains-twitter-exodus-science-medical-community-finds-alternative-to-x/

statnews.com

Bluesky is the new destination for X/Twitter’s health and science community. Here's why

#MedTwitter is migrating en masse from X to Bluesky, suddenly making it an essential hub for scientific discourse. Here's why.

0163

Reposted by Nico Gagelmann

Nihar Desai MD, DM @nihardesai7.bsky.social · 21/11/2024

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

43611